OIM
VIR icon

Oracle Investment Management’s Vir Biotechnology VIR Stock Holding History

Oracle Investment Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-383,700
Closed -$1.2M – 48
2021
Q3 		$1.2M Buy
+383,700
New +$16.6M 0.15% 27

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Oracle Investment Management's VIR Position: Q1 2022 in Review

Oracle Investment Management sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 861,008 shares — an estimated $36M sold.

Oracle Investment Management first reported a position in VIR in Q1 2021 and held it in 4 quarters. The position peaked at $51.4M in Q3 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

  • Oracle Investment Management reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Oracle Investment Management sold 861,008 Vir Biotechnology shares in Q1 2022, an estimated $36M.
  • Oracle Investment Management first reported a position in Vir Biotechnology in Q1 2021 and held it in 4 quarters.
  • Oracle Investment Management's Vir Biotechnology position peaked at $51.4M in Q3 2021.
  • 204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Oracle Investment Management's 13F filing for Q1 2022, filed 16 May 2022.